How and why do Australians obtain blood pressure devices for use at home? A mixed-methods study

ABSTRACT

Background Only 10-20% of blood pressure (BP) devices available are validated. Little is known about how and why patients choose BP devices for home BP measurement (HBPM), which was the aim of this study.

Methods Mixed-methods study (online survey (n=241), phone interviews among a purposive subsample (n=27)) among adults who perform HBPM in Australia (June-Dec 2023). Survey questions determined how BP devices were obtained, device make/model and factors influencing device selection. Interviews further explored these topics. Device validation status was determined using the STRIDE BP and Medaval websites.

Results Participants were middle aged (58±16 years, 52% women) and 91% purchased a device for HBPM (n=189; 9% borrowed a device), with 69% (n=130) purchased from pharmacies (53% validated) and 21% (n=39) purchased online (51% validated).

Accuracy was said to be the most important consideration when choosing a device for most participants (n=129, 77%). Interview participants described using brand recognition, online reviews and cost to select an ‘accurate’ device; avoiding cheaper devices and preferring brands used in healthcare settings. Participants did not consider validation status and did not receive advice on device accuracy at point-of-sale.

Conclusion This study highlights real world experiences of adults when obtaining HBPM devices that can be used to inform strategies to direct adults to validated devices. Strategies such as increasing signage at the point-of-sale and training healthcare practitioners to identify and direct consumers to validated devices may be effective in increasing uptake. Regulatory bodies should mandate the sale of validated devices in healthcare settings to increase availability.

• Download figure
• Open in new tab

Competing Interest Statement

Aletta E Schutte has received speaker fees from Omron, Medtronic, Aktiia, Servier, Sanofi, Novartis and is advisory board member for Skylabs and Abbott.

Funding Statement

Niamh Chapman is supported by a National Heart Foundation of Australia Postdoctoral Research Fellowship [2023-2024, #106657]. DSP is supported by a National Health and Medical Research Council Investigator Grant (GNT2018077) and is an Honorary Future Leader Fellow of the Heart Foundation of Australia (106618). Aletta E Schutte is supported by an NHMRC Investigator Leadership Grant [2023-2027, APP2017504).

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

This study was approved by the Human Research Ethics Committee of the University of Tasmania (H0028867) and informed consent was provided by all participants prior to participation.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.

Yes